# CJC-1295 Research Literature — Mechanism, Human Pharmacodynamics, and Detection Studies

> Detailed review of CJC-1295 research: GHRH receptor signaling cascade, Phase 1 human trial findings, pulsatility preservation data, proteomic downstream effects, and anti-doping detection methods.

A structured review of the primary literature: from the initial identification of the compound as a long-acting GRF analog in 2005 through the Phase 1 pharmacodynamic trials, the proteomic characterization studies, and the evolving anti-doping analytical literature of 2016 to 2025.

## What the studies actually show

The CJC-1295 research literature is narrow by the standards of approved medicines: two randomized, placebo-controlled Phase 1 trials in healthy adults, one animal normalization study in growth-hormone-deficient mice, one proteomic characterization study, a 2025 mechanistic review of the receptor it targets, and a growing collection of anti-doping analytical method papers. There are no large efficacy trials, no long-term safety data, and no studies in people who actually lack growth hormone. What the trials do show is a striking pharmacokinetic result — a single injection produced sustained elevations of growth hormone and its downstream signal (IGF-1) lasting days to nearly two weeks, while preserving the natural pulsatile pattern of GH secretion rather than replacing it. The pages below walk through each study, with specific dose cohorts, species, and measured outcomes clearly labeled.

## Receptor Mechanism: GHRH-R Signaling and the GH Secretory Cascade

CJC-1295 acts at the growth hormone-releasing hormone receptor (GHRH-R), a class II G-protein-coupled receptor expressed primarily on somatotroph cells of the anterior pituitary. The canonical signaling cascade, comprehensively mapped in a 2025 mechanistic review by Halmos et al., proceeds through Gs-protein coupling to adenylyl cyclase upon ligand binding [13]. The resulting elevation of intracellular cyclic AMP (cAMP) activates protein kinase A (PKA), which phosphorylates the transcription factor CREB at serine-133; CREB then binds cAMP response elements (CRE) within the GH gene promoter, upregulating GH mRNA synthesis and transcription [13]. Concurrent cAMP-mediated opening of voltage-dependent L-type calcium channels produces rapid calcium influx into somatotroph cytoplasm, triggering fusion of pre-formed GH-containing secretory granules with the plasma membrane — the immediate GH release event that precedes the transcriptional effect [13].

Secondary signaling pathways identified at the GHRH-R include phospholipase C (PLC) activation with generation of inositol trisphosphate (IP3) and diacylglycerol (DAG), and MAP kinase/ERK pathway activation mediating mitogenic effects on somatotrophs [13]. Splice variants of the GHRH-R, most notably the SV1 variant, retain cAMP signaling capability through alternate C-terminal domains, adding regulatory diversity to the receptor population's downstream signal output [13].

Because CJC-1295 acts at the upstream GHRH receptor rather than substituting for growth hormone itself, the somatostatin-mediated inhibitory tone that governs endogenous GH pulse timing remains active during CJC-1295 stimulation. Pulsatile GH secretion — characterized by discrete GH pulses predominantly during slow-wave sleep, driven by alternating GHRH stimulation and somatostatin withdrawal — is not abolished but amplified. This mechanism distinguishes GHRH analogs from exogenous growth hormone, which saturates feedback mechanisms and eliminates pulsatility entirely. The pharmacodynamic consequence was directly confirmed in human research: Ionescu and Frohman (2006) measured GH pulse frequency and magnitude after single injections of 60 or 90 mcg/kg CJC-1295 in healthy men and found neither parameter was significantly altered, while basal GH rose 7.5-fold and mean GH increased 46% [3].

## Animal Studies: Identification and GHRH-Knockout Normalization

The first published characterization of CJC-1295 appeared in Jette et al. (2005) in Endocrinology [1]. The study reported that hGRF1-29-albumin bioconjugates — the structural class to which CJC-1295 belongs — activated the GHRH receptor on anterior pituitary cells in Sprague-Dawley male rats, producing a 4-fold increase in GH area under the curve over two hours compared with native hGRF(1-29). Critically, CJC-1295 remained detectable in plasma by Western blot beyond 72 hours post-injection — a persistence approximately 400-fold greater than the unmodified peptide's expected duration. Enhanced stability against DPP-IV degradation was confirmed in cultured rat anterior pituitary cells [1].

Alba et al. (2006) extended the animal data to a model of pathological GH deficiency: GHRH-knockout mice (C57BL GHRHKO), which lack endogenous GHRH and display growth retardation, were treated with once-daily subcutaneous CJC-1295 at 2 mcg [4]. Once-daily administration normalized body weight, body length, bone development, and body composition in treated animals. Pituitary total RNA and GH mRNA increased significantly, and immunohistochemistry confirmed somatotroph cell proliferation. Dosing at every-48-hour or every-72-hour intervals produced diminished effects compared to once-daily treatment, establishing a frequency-dependence relationship in this specific model [4]. These knockout-normalization findings are mechanistic in character — they establish pharmacological proof of concept but do not translate directly to growth hormone deficiency in humans, a distinct clinical entity with a different pathophysiology.

## Human Phase 1 Trials: Pharmacokinetics and Pharmacodynamics

The most consequential data in the CJC-1295 evidence base come from two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adult humans. Teichman et al. (2006), published in the Journal of Clinical Endocrinology and Metabolism, enrolled subjects across four ascending dose levels: 30, 60, 120, and 180 mcg/kg subcutaneous [2]. The 30 and 60 mcg/kg cohorts demonstrated the most clinically interpretable pharmacodynamic profiles: dose-dependent 2- to 10-fold increases in mean plasma GH concentrations sustained for 6 or more days, IGF-1 elevations of 1.5- to 3-fold lasting 9 to 11 days, and no serious adverse reactions [2]. Multiple-dose administration — subcutaneous injections given bi-weekly — sustained IGF-1 above baseline for up to 28 days, consistent with expected cumulative pharmacokinetics from a depot-forming agent with a 5.8-to-8.1-day half-life [2].

Ionescu and Frohman (2006), also in JCEM, investigated pulsatility preservation specifically in healthy men aged 20 to 40 [3]. Single subcutaneous doses of 60 or 90 mcg/kg — no statistically significant difference was observed between these dose levels on pulsatility outcomes — produced basal GH elevation of 7.5-fold, overall mean GH increase of 46%, and IGF-1 increase of 45%. GH pulse frequency and magnitude were unchanged [3]. The preservation of pulse architecture under sustained tonic GHRH stimulation was mechanistically unexpected and represents a pharmacological distinction from continuous-infusion GH administration studies available in the literature at that time.

Sackmann-Sala et al. (2009) examined downstream proteomic perturbations following 60 to 90 mcg/kg single-dose CJC-1295 administration in 11 healthy adult males [5]. Two-dimensional gel electrophoresis and MALDI-TOF mass spectrometry identified five serum protein spots with significant intensity changes: apolipoprotein A1 and transthyretin decreased; beta-hemoglobin, a C-terminal albumin fragment, and an immunoglobulin fragment increased. A statistically significant linear correlation was identified between the immunoglobulin/albumin spot intensity and IGF-1 elevation (Pearson r2 = 0.668, P = 0.002) [5]. These proteomic shifts — downstream from the GH/IGF-1 axis activation — have not been followed up in subsequent publications, and their mechanistic significance remains uncharacterized.

## Anti-Doping Analytical Literature: Detection Methods and Regulatory Status

A substantial fraction of the post-2010 CJC-1295 literature addresses the analytical challenge of detecting the compound in biological matrices for anti-doping purposes. The albumin-bound form of CJC-1295 — which represents the predominant circulating species following subcutaneous injection — evades standard mass spectrometry detection because the covalent protein conjugate does not behave as a free peptide analyte [8]. Immunological methods are required for initial screening.

Henninge et al. (2010) first structurally confirmed CJC-1295 as a 29-amino acid peptide with C-terminal amide function in an illicit pharmaceutical preparation, using liquid chromatography-high resolution tandem mass spectrometry, and documented the compound's presence on the WADA S2 Prohibited List [7]. Timms et al. (2019) developed an immuno-PCR screening assay for equine plasma achieving a detection limit of 0.8 pg/mL, with a screening threshold of 50 pg/mL — noting that the albumin-conjugated form remained invisible to mass spectrometry approaches [8].

Knoop et al. (2016) validated an immunoaffinity purification method coupled with nano-UHPLC-HRMS/MS for qualitative detection of four GHRH analogs simultaneously — sermorelin, CJC-1293, CJC-1295, and tesamorelin — in human plasma below 50 pg/mL [9]. Coppieters et al. (2022) published an antibody-free ultrafiltration-based nanoLC-HRMS/MS method achieving limits of detection between 5 and 25 pg/mL and limits of identification between 25 and 50 pg/mL in urine [11]. Memdouh et al. (2021) characterized 19 in vitro metabolites of CJC-1295 and CJC-1295 DAC, achieving LC-MS/MS detection at approximately 1 ng/mL, and noted that despite documented use and investigator admissions, no CJC-1295 has been confirmed in WADA-accredited anti-doping samples [10]. Ucakturk and Nemutlu (2025) published a nano-LC/quadrupole-orbitrap method achieving limits of detection at or below 0.5 ng/mL for CJC-1295 and related GHRH analogs in urine [17], representing the current state of the art in anti-doping analytical capability for this compound class.

## Population Observations and Self-Reported Use

Van Hout and Hearne (2016) applied netnographic methodology to 23 online discussion threads involving female CJC-1295 users, documenting self-reported motivations including weight loss, muscle enhancement, skin rejuvenation, improved sleep quality, and injury recovery [12]. Users expressed awareness of gender variations in endogenous GH pulse patterns and their relevance to dose estimation — a pharmacokinetically sophisticated concern given that female GH pulsatility differs qualitatively from male patterns, complicating translation of the predominantly male Phase 1 trial data [12]. Poly-use of performance- and image-enhancing substances was common across the observed discussions. This netnographic work documents the de facto use landscape rather than the clinical research context; the observations are sociological in character and do not constitute pharmacological evidence.

---

An independent scholarly digest of the peer-reviewed CJC-1295 literature — not a clinic, not a vendor, not medical advice.